Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats. 1996

N Sugioka, and H Koyama, and T Ohta, and H Kishimoto, and T Yasumura, and K Takada
Department of Hospital Pharmacy, Kyoto Prefectural University of Medicine, Japan.

Mycophenolate mofetil (MPM), a new immunosuppressant, is the morpholinoethyl ester of mycophenolic acid (MPA). The distribution in blood and pharmacokinetics of MPA after administration of MPM were examined. The plasma to erythrocyte concentration ratio was low (0.10-0.15). MPA existed in rat plasma as the highly bound form (bound fraction was 9.79 +/- 0.57%). MPA disappeared from the systemic circulation with biexponential decay. After i.v. administration of MPM at the doses of 8.3, 16.7, and 33.3 mg/kg, the total clearance of MPA was 0.241 +/- 0.056, 0.321 +/- 0.126, and 0.317 +/- 0.092 L/h/kg, respectively. The terminal elimination half-live were 5.17 +/- 1.44, 8.89 +/- 2.76, and 7.94 +/- 2.94 h, respectively. After i.d. administration of MPM at the doses of 8.3, 16.7, 33.3, and 50.0 mg/kg, the terminal elimination half-live were 6.41 +/- 4.16, 4.49 +/- 2.20, 7.58 +/- 3.72, and 8.18 +/- 1.32 h, respectively. The mean peak times were within 30 min. The systemic availability of MPA after i.d. administration of MPM (at 8.3, 16.7, and 33.3 mg/kg) was calculated using the corresponding mean AUCiv, and the values were 84.3 +/- 35.0%, 69.9 +/- 25.7%, and 63.6 +/- 8.8%, respectively.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D009173 Mycophenolic Acid Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION. Cellcept,Mycophenolate Mofetil,Mycophenolate Mofetil Hydrochloride,Mycophenolate Sodium,Mycophenolic Acid Morpholinoethyl Ester,Myfortic,RS 61443,RS-61443,Sodium Mycophenolate,Mofetil Hydrochloride, Mycophenolate,Mofetil, Mycophenolate,Mycophenolate, Sodium,RS61443
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

N Sugioka, and H Koyama, and T Ohta, and H Kishimoto, and T Yasumura, and K Takada
September 1995, The Medical letter on drugs and therapeutics,
N Sugioka, and H Koyama, and T Ohta, and H Kishimoto, and T Yasumura, and K Takada
January 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
N Sugioka, and H Koyama, and T Ohta, and H Kishimoto, and T Yasumura, and K Takada
June 1998, Critical care nurse,
N Sugioka, and H Koyama, and T Ohta, and H Kishimoto, and T Yasumura, and K Takada
July 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
N Sugioka, and H Koyama, and T Ohta, and H Kishimoto, and T Yasumura, and K Takada
January 2001, Neurology,
N Sugioka, and H Koyama, and T Ohta, and H Kishimoto, and T Yasumura, and K Takada
June 1998, Clinical pharmacokinetics,
N Sugioka, and H Koyama, and T Ohta, and H Kishimoto, and T Yasumura, and K Takada
November 2000, Transplantation,
N Sugioka, and H Koyama, and T Ohta, and H Kishimoto, and T Yasumura, and K Takada
January 1998, Transplantation,
N Sugioka, and H Koyama, and T Ohta, and H Kishimoto, and T Yasumura, and K Takada
April 1996, Transplantation proceedings,
N Sugioka, and H Koyama, and T Ohta, and H Kishimoto, and T Yasumura, and K Takada
November 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society,
Copied contents to your clipboard!